Loading clinical trials...
Loading clinical trials...
A Randomised, Open-label, Multi-centre, Two-arm Phase 3 Study Comparing Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil to Trifluridine/Tipiracil Single Agent With a Safety Lead-In Part in Participants With KRAS/NRAS and BRAF Wild Type Metastatic Colorectal Cancer Previously Treated With Standard Treatment and Anti-EGFR Therapy
Conditions
Interventions
Futuximab/modotuximab
Trifluridine/Tipiracil
+1 more
Locations
15
United States
University of Michigan Oncology Clinic | Rogel Cancer Center
Ann Arbor, Michigan, United States
Cleveland Clinic Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio, United States
UZA Edegem
Edegem, Belgium
UZ Leuven Campus Gasthuisberg
Leuven, Belgium
CHUUCL Namur site Godinne
Yvoir, Belgium
Rigshospitalet
Copenhagen, Denmark
Start Date
April 21, 2022
Primary Completion Date
June 21, 2023
Completion Date
June 21, 2023
Last Updated
August 20, 2024
NCT07446322
NCT07536113
NCT07416552
NCT07228832
NCT04657068
NCT06625775
Lead Sponsor
Institut de Recherches Internationales Servier
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions